HERON’s Pricing and Reimbursement
Pricing and reimbursement decisions are one of the most important factors which determine the success of a product over its entire lifecycle. With a successful pricing strategy, launch delays and the potential of formulary exclusion can be greatly reduced, leading to optimal market access. A successful pricing strategy does not just involve identifying the revenue maximising prices. It also includes determining the product positioning, the evidence and activities required to best support the optimal pricing strategy.
HERON’s experience in supporting clients in this service spans refinement of strategic reimbursement positioning and payer research, to delivery of core value dossiers and local affiliate adaptation and workshop roll-outs. Following a review of HERON’s strategic goals it was decided to expand and enhance our capabilities in this key business area for our clients.
To this end, we have formed a dedicated practice, led by HERON’s P&R Director, Peter Hempshall who has extensive experience developing pricing and market access strategies for pharmaceutical clients’ products both pre- and post- launch. Prior to joining HERON, Peter worked within the Pricing and Market Access Practice of IMS Consulting, formerly known as Cambridge Pharma Consultancy.
The seamless combination of this new pricing and reimbursement team’s expertise and HERON’s proven evidence-based research excellence delivers unique benefits; these include the ability to optimise a product’s pricing and reimbursement strategy, while providing detailed recommendations that bridge the gap between strategic advice and implementation support.
In today’s climate where evidence-based medicine and value-for-money is becoming more and more the cornerstone to payers’ market access decisions; HERON is uniquely placed to provide evidence-based strategic and supporting advice, with confidence.
Please see our pricing & reimbursement services pages for further detail.